Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent ...

Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline ...

Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire -- Raised $3.6 million in registered direct offering in second quarter - REHOVOT ...

UChicago Medicine is launching a national cancer network to bring its academic medicine expertise to other communities in the ...

A large trial in a primary care setting found daily emollient use to be safe, feasible, and effective in reducing atopic ...

ICICI Securities is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 1570 in its research report dated August 19, 2025.

An announcement from Collplant Holdings ( ($CLGN) ) is now available. On August 20, 2025, CollPlant Biotechnologies reported its financial results ...

The Trump administration's ever-changing tariffs and Most Favored Nation drug pricing are part of a blizzard of unclear, ...

Trump calls for API stockpile, OCOchem to scale up chemicals from carbon dioxide, Covestro to buy isocyanates plants, and ...